Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves' disease

M. Rotondi, G. Mazziotti, B. Biondi, G. Manganella, A. Del Buono, P. Montella, M. Di Cristofaro, G. Di Lorio, G. Amato, Carlo Carella

Research output: Contribution to journalArticlepeer-review


Interferon (IFN)-β has become a widespread therapy for multiple sclerosis. As already reported for IFN-α, thyroid autoimmunity and dysfunctions have been observed also in course of IFN-β therapy. Nevertheless, very few cases of Graves' disease, occurred in such condition, have been reported in literature. We here describe the case of a 40-year-old female affected by multiple sclerosis, who received IFN-β-1b, 8 million IU sc every other day for her condition. After 22 months of cytokine administration, she developed a severe Graves' disease with persistently positive TRAb which suggested the withdrawal of the treatment. Our patient had performed a complete thyroid evaluation with normal findings, before and during the first 6 months of therapy. This case suggests that patients undergoing long-term IFN-β therapy should be monitored for thyroid hormones and antibodies throughout the treatment as thyroidal side effect can be a late event. (C)2000, Editrice Kurtis.

Original languageEnglish
Pages (from-to)321-324
Number of pages4
JournalJournal of Endocrinological Investigation
Issue number5
Publication statusPublished - 2000


  • Cytokines
  • Graves
  • Hyperthyroidism
  • IFN-β
  • Multiple sclerosis
  • Thyroid autoimmunity
  • TRAb

ASJC Scopus subject areas

  • Endocrinology


Dive into the research topics of 'Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves' disease'. Together they form a unique fingerprint.

Cite this